amr-accelerator.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

Hear from Carina Matias, as she shares her contribution is shaping reproducibility and clinical relevance in AMR research via COMBINE Project. In this interview, she provides insight into: 🧪 Drug Development 🤝 Global Collaboration 💻 AI Discovery 🔗 Read full interview: https://bit.ly/4lknOvI

submitted 11 hours ago • 0 comments

𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝗧𝗕 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗮 𝗺𝗼𝗿𝗲 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆? This work presents a protocol that combines two methods to better quantify MTB in time-kill assays. 🔍 More accurate data = better TB drugs. ⠀ 👉 𝗦𝘄𝗶𝗽𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗵𝗼𝘄 𝘄𝗲 𝗱𝗼 𝗶𝘁. @era4tb.bsky.social

submitted 5 days ago • 0 comments

Don't miss the chance to attend the UNITE4TB webinar! Join to learn on revolutionizing TB diagnosis: moving beyond sputum with innovative, noninvasive tools that improve detection, guide care and drive change. 🗓️ 26 June 2025 ⏰ 13:00-14:00 CEST 🔗 Register now: bit.ly/3FG8sm7

submitted 7 days ago • 0 comments

Same medicine, but different outcomes. Why does this happen and what can we do about it? In our recent work, we unpack interoccasion variability. A key factor in how we model drug behavior and build smarter clinical studies. 👉 Swipe to learn more.

submitted 12 days ago • 0 comments

Hear from Leonie von Berlin, as she shares how FAIR data practices power innovation across AMR Accelerator projects. In this interview, she talks about 🧬 Unified infrastructure 🤖 Enabling ML in antimicrobial R&D 🌍 Promoting open, global science 🔗 Read full interview: https://bit.ly/45zTOaD

submitted 14 days ago • 0 comments

Good luck to all the ERA4TB consortium members presenting at PAGE 2025 this week. www.page-meeting.org/default.asp?... #TBSky #TBResearch #Tuberculosis

submitted 19 days ago • 0 comments

How far can a petri dish take us in the fight against MRSA? 🧫 Using translational modelling, from in vitro to mouse models, we go further than you’d think ! Have a look at: 🔍 What we did 💡 Why it matters 🚀 Where it leads More about the paper on our site. amr-accelerator.eu/publications/

submitted 19 days ago • 0 comments

How is ML shaping smarter drug discovery? 💊 In our recent young researchers interview, Yojana Gadiya shares her work on an ML-powered Antimicrobial Knowledge Graph, FAIR MIC dataset and the promise of generative models. Full interview: amr-accelerator.eu/news/intervi... @fraunhoferitmp.bsky.social

submitted 21 days ago • 0 comments

Even with sparse data & imperfect surrogates, a flexible Bayesian framework can guide early decisions in MAMS Phase II trials. Via UNITE4TB. 📄 Read the complete paper at: bit.ly/43wjZfw ℹ️ For more information: bit.ly/42Yob7r #ClinicalTrials #AMR #TB #tuberculosis

submitted 22 days ago • 0 comments

Recently, our experts discussed endolysins, from concept to first-in-human trials and shared insights on breakthroughs, challenges & the future of antimicrobials. 📺 Watch: bit.ly/43u5bxV 🌐 Learn more: bit.ly/43eNkfG #AMR #webinar #Biotech

submitted 28 days ago • 0 comments

And the ERA4TB 9th Consortium Meeting is over! Thanks to our host, @www.unizar.es, all our partners, our key-note speakers and the Scientific Advisory Board members for their attendance and insightful contributions. @pasteur.fr @amr-accelerator.bsky.social @ihieurope.bsky.social

submitted 33 days ago • 0 comments

Must Read: As TB remains a global challenge, drug trial innovation must center voices who face the barriers. A research by Villa S. et al. (UNITE4TB Consortium) offers policy steps for more inclusive, effective TB trials. 🔗 Paper: bit.ly/4mrlV1A 🔗 Info: bit.ly/42Yob7r

submitted 33 days ago • 0 comments

Our May Newsletter just dropped! This month, we’re celebrating the brilliant women driving innovation in the AMR Accelerator. Inspired by Women’s Day, we’re sharing three interviews with outstanding female researchers in our community. Catch up here: bit.ly/4j6uHPv

submitted 34 days ago • 1 comment

Prof Stewart Cole from @institutpasteur.bsky.social is presenting now at the ERA4TB annual meeting. Watch here: tinyurl.com/4p62eje3 @www.unizar.es @ineosoxford.bsky.social @ema.europa.eu @gatesfoundation.bsky.social @amr-accelerator.bsky.social @ihieurope.bsky.social @tballiance.bsky.social

submitted 35 days ago • 0 comments

🎉 New study from COMBINE consortium ! This study is the first to use a standardized mouse pneumonia model for Gram-positive bacteria. It advances PKPD modeling of LZD & VAN for better antibiotic strategies. 🔗 Read at: bit.ly/3F6iTPy 👉 For more info: bit.ly/42Yob7r #MRSA #AMR#TranslationalResearch

submitted 40 days ago • 0 comments

🎉 @evotec.bsky.social, our partner in COMBINE and @era4tb.bsky.social received a $2.5M @gatesfoundation.bsky.social grant to develop next-gen TB treatments! A big step toward faster, more effective regimens. 💊🔬 🔗 Read at: hubs.ly/Q03ldQ2b0 #Evotec #Tuberculosis #AM

submitted 41 days ago • 0 comments

A major step in TB research: A culture-free biomarker assay that quantifies bacillary load fast and accurately, no lab culture needed. This could potentially speed up drug trials and treatment. 🔬 Read the study via UNITE4TB in @thelancet.bsky.social at bit.ly/4iVmPAu For more info: bit.ly/42Yob7r

submitted 43 days ago • 0 comments

𝗘𝗻𝗷𝗼𝘆𝗶𝗻𝗴 𝗮 𝗟𝗼𝗻𝗴 𝗕𝗿𝗲𝗮𝗸 𝗪𝗵𝗲𝗻 𝗢𝘂𝗿 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗪𝗲𝗻𝘁 𝗟𝗶𝘃𝗲? 𝗡𝗼 𝗪𝗼𝗿𝗿𝗶𝗲𝘀! Watch the recorded webinar on health economics & TB treatment development here: 🔗 youtu.be/HSsMa8hqfOQ 👉 Learn more: amr-accelerator.eu/public-webin... #AMR #Webinar #HealthEconomics #Tuberculosis @era4tb.bsky.social

submitted 49 days ago • 1 comment

Must Read: '𝗔 𝗵𝗶𝗴𝗵-𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝘁𝗮𝗿𝗴𝗲𝘁-𝗯𝗮𝘀𝗲𝗱 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗼𝗳 𝗠𝘆𝗰𝗼𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝘂𝗺 𝘁𝘂𝗯𝗲𝗿𝗰𝘂𝗹𝗼𝘀𝗶𝘀 𝗺𝘆𝗰𝗼𝘁𝗵𝗶𝗼𝗻𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗮𝘀𝗲 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀.' by Smiejkowska N. et al. 👉 𝗥𝗲𝗮𝗱 𝗮𝘁 journals.asm.org/doi/10.1128/... #Tuberculosis #DrugDiscovery #AMR #Research

submitted 54 days ago • 0 comments

🎉 Big news from the UNITE4TB Consortium! New publication out: 'Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations.' 📄 Read at: link.springer.com/article/10.1... #AMR #EndTB #Research #Innovation

submitted 56 days ago • 0 comments

This year the ERA4TB annual meeting key note speeches will be available to watch live online! Join us on 20-21 May to hear about 'a world without antibiotics', regulatory affairs and TB vaccines. 🔷Registration link to be released next week! 🔷 #Tuberculosis #TBSky @www.unizar.es @pasteur.fr

submitted 61 days ago • 0 comments

Interesting read: '𝗘𝘅𝗰𝗲𝘀𝘀 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲 𝘂𝘀𝗲 𝗮𝗻𝗱 𝗰𝗼𝘀𝘁 𝗼𝗳 𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝘀𝗶𝘅 𝗸𝗲𝘆 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝘀 𝗶𝗻 𝗘𝘂𝗿𝗼𝗽𝗲: 𝗮 𝘀𝘆𝘀𝘁𝗲𝗺𝗮𝘁𝗶𝗰 𝗿𝗲𝘃𝗶𝗲𝘄 𝗮𝗻𝗱 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗺𝗲𝘁𝗮-𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀.' by Kingston et al. 👉 Read the paper at: www.clinicalmicrobiologyandinfection.com/article/S119... #AMR #HealthEconomics #GlobalHealth

submitted 61 days ago • 0 comments

Missed one of our webinars? Now you can catch up on all recordings, available on our site! 🧠 Expert insights 📊 Emerging research 🏥 For researchers, policymakers & health pros 👉 Watch now: amr-accelerator.eu/public-webin... #Webinar #HResearch #webinars #PublicHealth

submitted 63 days ago • 0 comments

Data on vaccines & mAbs is often too limited, too broad or just not broken down enough. 𝗡𝗼 𝗮𝗴𝗲, 𝘀𝗲𝘅, 𝗰𝗼𝗺𝗼𝗿𝗯𝗶𝗱𝗶𝘁𝗶𝗲𝘀 = 𝗻𝗼 𝘁𝗮𝗿𝗴𝗲𝘁 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 = 𝗻𝗼 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆. Robotham et al discusses on open, granular AMR data inclusion. 👉Read at : doi:10.1016/j.cmi.2023.10.004 #AMR #Vaccines #PublicHealth #Research

submitted 68 days ago • 0 comments

Explore the 'Tools and Resources' page designed to boost your AMR research in all the stages from early discovery to approaching clinical validation. 👉 amr-accelerator.eu/tools-and-re... #AMR #Innovation #PublicHealth #ResearchTools

submitted 70 days ago • 0 comments

Our researchers will present data on a model for MRSA at ESCMID Global 2025! 📌 Visit the poster located in Sector B; Row 10 and position 18. 🗓️ 13th April, 2025, 12:00 - 13:30 CEST. 👉 For more details visit: amr-accelerator.eu/news/09-04-2... #ESCMIDGlobal #ESCMID2025 #AMR #scientificposter

submitted 75 days ago • 0 comments

𝗧𝗕 𝗰𝗼𝘀𝘁𝘀 𝗘𝘂𝗿𝗼𝗽𝗲 𝗯𝗶𝗹𝗹𝗶𝗼𝗻𝘀, 𝗯𝘂𝘁 𝗲𝘃𝗲𝗿𝘆 €𝟭 𝗶𝗻𝘃𝗲𝘀𝘁𝗲𝗱 𝗳𝗶𝗴𝗵𝘁𝘀 𝗯𝗮𝗰𝗸 𝘄𝗶𝘁𝗵 €𝟰𝟯 𝗶𝗻 𝗿𝗲𝘁𝘂𝗿𝗻𝘀! Join us as we discuss the TB's global cost burden on health systems and patients. 🗓️ 9 April 2025 ⏰ 15:00 - 16:00 CEST 👉Register now forms.biocom.de/index.php/68... #Webinar #AMR #TB #healtheconomics #cost #health

submitted 77 days ago • 0 comments

Must read: “𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝗰𝘆 𝗼𝗳 𝗯𝗹𝗼𝗼𝗱𝘀𝘁𝗿𝗲𝗮𝗺 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗰𝗮𝘂𝘀𝗲𝗱 𝗯𝘆 𝘀𝗶𝘅 𝗸𝗲𝘆 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝘀 𝗳𝗼𝗿 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗼𝗳 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗘𝘂𝗿𝗼𝗽𝗲: 𝗮 𝘀𝘆𝘀𝘁𝗲𝗺𝗮𝘁𝗶𝗰 𝗿𝗲𝘃𝗶𝗲𝘄” by Pezzani M, et al. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁 www.clinicalmicrobiologyandinfection.com/article/S119...

submitted 82 days ago • 0 comments

𝗢𝘂𝗿 𝗻𝗲𝘅𝘁 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗱𝗿𝗼𝗽𝘀 𝗶𝗻 𝗠𝗮𝘆, 𝗮𝗻𝗱 𝗶𝘁’𝘀 𝗽𝗮𝗰𝗸𝗲𝗱 𝘄𝗶𝘁𝗵 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝗳𝘂𝗹 𝗰𝗼𝗻𝘁𝗲𝗻𝘁! 🚀 𝗖𝗼𝗺𝗶𝗻𝗴 𝗻𝗲𝘅𝘁: - A spotlight piece on COMBINE - Exclusive interviews - More webinars In the meantime, let's subscribe so you don’t miss it! 🔗https://shorturl.at/UM3DJ #Newsletter #COMBINE #AMR #SubscribeNow

submitted 84 days ago • 0 comments

Read about the overlooked critical parameters in the HFS-TB experiments and their impact on experimental conclusions. Highlights: ✅ Drug–fibre compatibility ✅ Sampling method ✅ Bacterial adaptation period 👉 Read the complete paper at bpspubs.onlinelibrary.wiley.com/doi/10.1111/...

submitted 89 days ago • 0 comments

Amazing to see our colleagues, Santi, Ainhoa and Cris from the University of Zaragoza on TV today for World TB day discussing the work they have been undertaking on developing new TB treatments! #WorldTBday2025 #WorldTBday #TBSky @ihieurope.bsky.social @amr-accelerator.bsky.social

submitted 92 days ago • 0 comments

Today is World TB Day and we reaffirm our commitment to combating tuberculosis through innovation, collaboration and action. @ihieurope.bsky.social ERA4TB UNITE4TB RespiriTB TRICTB #WorldTBDay #worldtbday2025 #YesWeCanEndTB #EndTB #WHO

submitted 92 days ago • 0 comments

Another Milestone for @era4tb.bsky.social Consortium! 🎉 New research paper published on implementing best practices on data generation and reporting of Mycobacterium tuberculosis 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 assays. 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗵𝗲 𝗣𝗮𝗽𝗲𝗿 📜 🔗 www.sciencedirect.com/science/arti... #AMR #EndTB #MedicalResearch #Innovation

submitted 96 days ago • 0 comments

Yes! We Can End TB: Commit, Invest,Deliver. This year's WHO theme calls for optimism, action and responsibility and we at AMR Accelerator are inspired. Join us for our next webinar with health economics experts to explore TB's global cost burden. 👉 Register now: forms.biocom.de/index.php/68...

submitted 98 days ago • 0 comments

For #InternationalWomensDay2025 we have asked our members why they feel it is important for women to be involved in TB research and what they would like to see happen in the world to #AccelerateAction. Stay posted over the next couple of weeks to hear more! @ihieurope.bsky.social

submitted 103 days ago • 0 comments

Did you know ? Alpibectir is a novel potent anti-TB drug. 👉 Read "𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗮𝗹𝗽𝗶𝗯𝗲𝗰𝘁𝗶𝗿 (𝗕𝗩𝗟-𝗚𝗦𝗞𝟬𝟵𝟴), 𝗮 𝗻𝗼𝘃𝗲𝗹 𝗽𝗼𝘁𝗲𝗻𝘁 𝗮𝗻𝘁𝗶-𝗧𝗕 𝗱𝗿𝘂𝗴" by Pieren et al., 2024 at academic.oup.com/jac/article/... #TBResearch #DrugDevelopment #Innovation #AMR

submitted 103 days ago • 0 comments

Last month, we took a deep dive into how our researchers developed a ML model which can help identify new antimicrobial compounds. Check out the key takeaways and watch the recording of our webinar on ML in combating AMR. 👉 Watch here: amr-accelerator.eu/public-webin... #AMR #webinar #recording #ML

submitted 105 days ago • 0 comments

𝗜𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗶𝗻𝗴 𝗿𝗲𝗮𝗱: “Using contact network dynamics to implement efficient interventions against pathogen spread in hospital settings: A modelling study” by Leclerc et al., explores MRSA transmission with an individual-based model. Read at doi.org/10.1371/jour...

submitted 110 days ago • 1 comment

HY-133, a phage lysin targeting S. aureus & MRSA, is in Phase I trials. Join our exclusive COMBINE webinar to learn more on such success stories in research on novel antibiotics and innovative antibacterial approaches. 👉 Register now: limesurvey.biocom.de/index.php/45... #AMR #resistance #webinar

submitted 112 days ago • 0 comments

The second day of #AMRconference in Basel! Come to our @amr-accelerator.bsky.social Booth 12 at 13:30 today to talk to Carina Vingsbo-Lundberg (Statens Serum Institut) about the COMBINE standard murine pneumonia model! @fderoose.bsky.social and I will be happy to say hi whenever you have time!

submitted 118 days ago • 0 comments

It's already getting busy at the #AMRconference in Basel! Come say hi to me and @fderoose.bsky.social at the @amr-accelerator.bsky.social booth 12!

submitted 119 days ago • 1 comment

⚡ NEW: Research paper on an #AI model that can indicate which compounds perform better against various strains of bacteria, aiding the fight against #AMR. Read our interview with the lead researcher here 👇 europa.eu/!n7QCqY #IHITransformingHealth #HorizonEU #EUResearch @amr-accelerator.bsky.social

submitted 120 days ago • 0 comments

Our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗽𝗮𝗽𝗲𝗿 𝗯𝘆 𝗬𝗼𝗷𝗮𝗻𝗮 𝗚𝗮𝗱𝗶𝘆𝗮 𝗮𝗻𝗱 𝗣𝗵𝗶𝗹𝗶𝗽 𝗚𝗿𝗶𝗯𝗯𝗼𝗻, discusses the main features of the new ML model which is trained on publicly available 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 data and furthermore is customizable and open source. 👉 Read the full article at pubs.acs.org/doi/10.1021/... @ihieurope.bsky.social #AMR #ML

submitted 120 days ago • 1 comment